Lawrence G Lum

List of Publications by Year
in descending order

110 papers	3,104 citations	147801 31 h-index	182427 51 g-index
111 all docs	111 docs citations	111 times ranked	3134 citing authors

#	Article	IF	Citations
1	Transfer of Allergen-Specific IgE-Mediated Hypersensitivity with Allogeneic Bone Marrow Transplantation. New England Journal of Medicine, 1988, 319, 1623-1628.	27.0	186
2	Specific Humoral Immunity in the Elderly: in vivo and in vitro Response to Vaccination. Journal of Gerontology, 1993, 48, B231-B236.	1.9	138
3	Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treatment Reviews, 2010, 36, 528-538.	7.7	123
4	Bispecific antibody based therapeutics: Strengths and challenges. Blood Reviews, 2018, 32, 339-347.	5.7	120
5	Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study. Clinical Cancer Research, 2006, 12, 1859-1867.	7.0	114
6	Anti-CD3 Ã— Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model. Clinical Cancer Research, 2006, 12, 183-190.	7.0	96
7	Use of Anti-CD3 Ã— Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu+Tumors. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 247-260.	1.8	85
8	Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial. Clinical Cancer Research, 2015, 21, 2305-2314.	7.0	85
9	Antibody Targeting of Stem Cells to Infarcted Myocardium. Stem Cells, 2007, 25, 712-717.	3.2	78
10	Human T Cells Armed with Her2/neu Bispecific Antibodies Divide, Are Cytotoxic, and Secrete Cytokines with Repeated Stimulation. Clinical Cancer Research, 2006, 12, 569-576.	7.0	70
11	Antiâ€CD3â€‰Ã—â€‰antiâ€GD2 bispecific antibody redirects Tâ€cell cytolytic activity to neuroblastoma targets. Pediatric Blood and Cancer, 2012, 59, 1198-1205.	1.5	70
12	Marrow transplant experience in children with acute lymphoblastic leukemia: An analysis of factors associated with survival, relapse, and graft-versus-host disease. Medical and Pediatric Oncology, 1985, 13, 165-172.	1.0	69
13	Cancer Immunology and Immunotherapy. Anticancer Research, 2016, 36, 5593-5606.	1.1	69
14	In vitro regulation of immunoglobulin synthesis by T-cell subpopulations defined by a new human T-cell antigen (9.3). Cellular Immunology, 1982, 72, 122-129.	3.0	64
15	Immune Recovery After Bone Marrow Transplantation. Hematology/Oncology Clinics of North America, 1990, 4, 659-675.	2.2	57
16	T cells armed with anti-CD3 Ã— anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Experimental Hematology, 2005, 33, 452-459.	0.4	57
17	Induction of Specific Cellular and Humoral Responses Against Renal Cell Carcinoma After Combination Therapy With Cryoablation and Granulocyte-Macrophage Colony Stimulating Factor. Journal of Immunotherapy, 2011, 34, 457-467.	2.4	53
18	Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. Prostate Cancer, 2015, 2015, 1-10.	0.6	53

#	Article	IF	Citations
19	THYMUS TRANSPLANTATION AFTER ALLOGENEIC BONE MARROW GRAFT TO PREVENT CHRONIC GRAFT-VERSUS-HOST DISEASE IN HUMANS. Transplantation, 1982, 33, 168-173.	1.0	49
20	The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. Journal of Clinical Immunology, 1986, 6, 389-396.	3.8	45
21	A Th1 cytokineâ€“enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy, 2012, 61, 497-509.	4.2	45
22	Cancer therapy with bispecific antibodies: Clinical experience. Current Opinion in Molecular Therapeutics, 2010, 12, 340-9.	2.8	45
23	Decreased specific antibody synthesis in old adults: Decreased potency of antigen-specific B cells with aging. Mechanisms of Ageing and Development, 1990, 53, 229-241.	4.6	43
24	Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28â€“Costimulated T Cellsâ€”Phase I Clinical Trial. Journal of Immunotherapy, 2001, 24, 408-419.	2.4	42
25	IMMUNOLOGIC RECOVERY IN HUMAN MARROW GRAFT RECIPIENTS GIVEN CYCLOSPORINE OR METHOTREXATE FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE. Transplantation, 1984, 37, 456-460.	1.0	39
26	Preclinical Studies Using Immobilized OKT3 to Activate Human T Cells for Adoptive Immunotherapy: Optimal Conditions for the Proliferation and Induction of Non-MHC-Restricted Cytotoxicity. Clinical Immunology and Immunopathology, 1994, 70, 234-240.	2.0	38
27	Prevention of Hemorrhagic Cystitis Following Allogeneic Bone Marrow Transplant Preparative Regimens With Cyclophosphamide and Busulfan: Role of Continuous Bladder Irrigation. Journal of Urology, 1995, 153, 637-640.	0.4	38
28	â€œNextGenâ€•Biologics: Bispecific Antibodies and Emerging Clinical Results. Expert Opinion on Biological Therapy, 2016, 16, 675-688.	3.1	37
29	Targeting T Cells with Bispecific Antibodies for Cancer Therapy. BioDrugs, 2011, 25, 365-379.	4.6	36
30	CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biology of Blood and Marrow Transplantation, 2013, 19, 925-933.	2.0	35
31	Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR) Tj ETQq1 1 0.784314 rgBT	4.6	34
32	Anti-CD3 Ã— Anti-HER2 Bispecific Antibody Effectively Redirects Armed T Cells to Inhibit Tumor Development and Growth in Hormone-Refractory Prostate Cancerâ€“Bearing Severe Combined Immunodeficient Beige Mice. Clinical Prostate Cancer, 2004, 3, 112-121.	2.1	33
33	Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. Journal of Translational Medicine, 2014, 12, 347.	4.4	32
34	Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer, 2004, 100, 1095-1103.	4.1	31
35	The new face of bispecific antibodies: targeting cancer and much more. Experimental Hematology, 2006, 34, 1-6.	0.4	31
36	Scutellaria extract and wogonin inhibit tumor-mediated induction of Treg cells via inhibition of TGF-Î²1 activity. Cancer Immunology, Immunotherapy, 2012, 61, 701-711.	4.2	31

#	Article	IF	Citations
37	Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway. Journal of Translational Medicine, 2013, 11, 35.	4.4	31
38	Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer, 2013, 13, 83.	2.6	31
39	Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal. Oncotarget, 2016, 7, 6121-6135.	1.8	30
40	Targeting of Linâ^'Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium. Blood Cells, Molecules, and Diseases, 2004, 32, 82-87.	1.4	29
41	Targeting human CD34⁺ hematopoietic stem cells with anti-CD45 Ã— anti-myosin light-chain bispecific antibody preserves cardiac function in myocardial infarction. Journal of Applied Physiology, 2008, 104, 1793-1800.	2.5	28
42	Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2016, 91, E341-7.	4.1	25
43	Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 273-291.	0.5	25
44	PRECLINICAL STUDIES FOR ADOPTIVE IMMUNOTHERAPY IN BONE MARROW TRANSPLANTATION. Transplantation, 1993, 56, 351-355.	1.0	24
45	Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. , 2021, 9, e002222.		24
46	The immunological contribution of NF-ÎºB within the tumor microenvironment: A potential protective role of zinc as an anti-tumor agent. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 160-172.	7.4	23
47	Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. Journal of Translational Medicine, 2014, 12, 191.	4.4	23
48	Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine, 2018, 59, 410-417.	5.0	23
49	Maspin expression in prostate tumor elicits host anti-tumor immunity. Oncotarget, 2014, 5, 11225-11236.	1.8	22
50	Phase I/II Study of Treatment of Stage IV Breast Cancer with OKT3 x Trastuzumabâ€“Armed Activated T Cells. Clinical Breast Cancer, 2003, 4, 212-217.	2.4	21
51	Targeting Cytomegalovirus-Infected Cells Using T Cells Armed with Anti-CD3 Ã— Anti-CMV Bispecific Antibody. Biology of Blood and Marrow Transplantation, 2012, 18, 1012-1022.	2.0	19
52	Generation and immunologic functions of Th17 cells in malignant gliomas. Cancer Immunology, Immunotherapy, 2013, 62, 75-86.	4.2	19
53	Immunotherapy and Immune Evasion in Prostate Cancer. Cancers, 2013, 5, 569-590.	3.7	19
54	BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 531-535.	0.4	18

#	Article	IF	Citations
55	Immune T cells can transfer and boost anti-breast cancer immunity. OncoImmunology, 2018, 7, e1500672.	4.6	18
56	ANTIGEN-SPECICIC ANTIBODY RESPONSES OF LYMPHOCTYES TO TETANUS TOXOID AFTER HUMAN MARROW TRANSPLANTATION. Transplantation, 1986, 41, 587-592.	1.0	17
57	Effect of disruption of Akt-1 of lin-c-kit+ stem cells on myocardial performance in infarcted heart. Cardiovascular Research, 2010, 87, 704-712.	3.8	17
58	Activated T cells armed with bispecific antibodies kill tumor targets. Current Opinion in Hematology, 2015, 22, 476-483.	2.5	17
59	Activated T-Cell and Bispecific Antibody Immunotherapy for High-Risk Breast Cancer. Acta Haematologica, 2001, 105, 130-136.	1.4	16
60	Targeting CD138â^'/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity. Biology of Blood and Marrow Transplantation, 2016, 22, 869-878.	2.0	16
61	Phase II clinical trial using anti-CD3 Ã— anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0â€“2+) metastatic breast cancer. , 2021, 9, e002194.		16
62	In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells. Cancer Immunology, Immunotherapy, 2011, 60, 1707-1720.	4.2	15
63	IgG anti-tetanus toxoid antibody synthesis by human bone marrow. I. Two distinct populations of marrow B cells and functional differences between marrow and peripheral blood B cells. Journal of Clinical Immunology, 1990, 10, 255-264.	3.8	14
64	Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas. Anticancer Research, 2005, 25, 43-52.	1.1	14
65	Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2007-2016.	2.5	13
66	Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. Journal of Hematology and Oncology, 2021, 14, 204.	17.0	13
67	Pan-Bcl-2 Inhibitor AT-101 Enhances Tumor Cell Killing by EGFR Targeted T Cells. PLoS ONE, 2012, 7, e47520.	2.5	12
68	PHENOTYPICAL AND FUNCTIONAL STUDIES ON A SUBTYPE OF SUPPRESSOR CELLS (CD8+/CD11+) IN PATIENTS AFTER BONE MARROW TRANSPLANTATION. Transplantation, 1987, 44, 381-386.	1.0	11
69	Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients. Supportive Care in Cancer, 2017, 25, 2593-2601.	2.2	11
70	Anti-CS1 Ã— Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines. Frontiers in Oncology, 2020, 10, 544.	2.8	11
71	Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells. Frontiers in Immunology, 2021, 12, 690437.	4.8	11
72	Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs. Expert Opinion on Biological Therapy, 2019, 19, 707-720.	3.1	10

#	Article	IF	Citations
73	Bispecific antibodies for the treatment of breast cancer. Expert Opinion on Biological Therapy, 2022, 22, 1017-1027.	3.1	10
74	IgG anti-tetanus toxoid antibody production induced by Epstein-Barr virus from B cells of human marrow transplant recipients. Cellular Immunology, 1986, 101, 266-273.	3.0	9
75	Immunodeficiency and the role of suppressor cells after human bone marrow transplantation. Clinical Immunology and Immunopathology, 1992, 63, 103-109.	2.0	9
76	Hematopoietic Cell Transplantation and Cellular Therapeutics in the Treatment of Childhood Malignancies. Pediatric Clinics of North America, 2015, 62, 257-273.	1.8	9
77	In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer. OncoImmunology, 2016, 5, e1055061.	4.6	9
78	In vitro immunoglobulin production, proliferation, and cell markers before and after antithymocyte globulin therapy in patients with aplastic anemia. American Journal of Hematology, 1987, 26, 1-15.	4.1	7
79	Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness. OncoImmunology, 2021, 10, 1930883.	4.6	7
80	LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer. Oncogene, 2022, 41, 2054-2068.	5.9	7
81	The regulatory roles of T4 and T8 subsets in tetanus toxoid-induced in vitro immunoglobulin production. Cellular Immunology, 1983, 82, 184-195.	3.0	6
82	Activated T cells from umbilical cord blood armed with antiâ€CD3 Ã— antiâ€CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants. Transfusion, 2012, 52, 63-75.	1.6	6
83	Recapitulation of immune ontogeny: A vital component for the success of bone marrow transplantation. Cancer Treatment and Research, 1990, 50, 27-54.	0.5	6
84	Infusions of T Cells Armed with Anti-CD3 x Anti-Her2/neu Bispecific Antibody Modulate In Vivo Patient Immune Responses in Phase I Clinical Trials for Breast and Hormone Refractory Prostate Cancers.. Blood, 2004, 104, 1349-1349.	1.4	6
85	Phase I/II Study of Treatment of Stage IV Breast Cancer with OKT3 x Trastuzumabâ€"Armed Activated T Cells. Clinical Breast Cancer, 2003, 4, 212-217.	2.4	5
86	Is the Leuocyte groupâ€5a antigen associated with reduced NK cell function?. Tissue Antigens, 1985, 25, 107-110.	1.0	5
87	Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS). , 2015, 3, P55.		5
88	Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE). Cancer Immunology, Immunotherapy, 2021, 70, 633-656.	4.2	5
89	Targeting advanced pancreatic cancer with activated t cells armed with anti-CD3 x anti-EGFR bispecific antibody.. Journal of Clinical Oncology, 2018, 36, 4108-4108.	1.6	5
90	Broad reactivity and enhanced potency of recombinant anti-EGFRâ€‰Ã—â€‰anti-CD3 bispecific antibody-armed activated T cells against solid tumours. Annals of Medicine, 2022, 54, 1047-1057.	3.8	4

#	Article	IF	Citations
91	Development and prospects for bispecific antibody-based therapeutics in cancer and other applications. Expert Opinion on Drug Discovery, 2008, 3, 1081-1097.	5.0	3
92	Bispecific Antibody Armed T Cells to Target Cancer Cells. Methods in Molecular Biology, 2018, 1722, 117-126.	0.9	3
93	Arming â€œold guardsâ€•with â€œnew dual-targeting weaponsâ€: Cancer Cell, 2021, 39, 604-606.	16.8	3
94	Human Stem Cells Armed with Bispecific Antibodies Home to Injury-Specific Molecules in Myocardial Infarcts in Nude Rats.. Blood, 2004, 104, 2697-2697.	1.4	3
95	How Important Is HER2/neu Amplification and Expression when Selecting Patients for HER2/neuâ€“Targeted Therapies?. Clinical Breast Cancer, 2004, 5, 70-71.	2.4	2
96	Virtual reality of stem cell transplantation to repair injured myocardium. Journal of Cellular Biochemistry, 2005, 95, 869-874.	2.6	2
97	Bispecific Antibodies for Arming Activated T Cells and Other Effector Cells for Tumor Therapy. , 2011, , 243-271.		2
98	Mini-Haploidentical Transplantation for Refractory Acute Myeloid Leukemia.. Blood, 2004, 104, 2150-2150.	1.4	2
99	Immunology and Immunotherapy of Head and Neck Cancer. , 2003, , 569-591.		1
100	Phase I Trial of Multiple Infusions of Autologous Activated T Cells with Anti-CD3 x Anti-CD20 Bispecific Antibody (CD20Bi) after Autologous Peripheral Blood Stem Cell Transplant for NonHodgkins Lymphoma To Improve Graft-vs-Lymphoma Effects.. Blood, 2007, 110, 4488-4488.	1.4	1
101	Transfer of anti-breast cancer immunity induced by infusions of bispecific antibody armed T cells and boosted with ex vivo primed T cells after stem cell transplant in metastatic breast cancer patients.. Journal of Clinical Oncology, 2015, 33, 3076-3076.	1.6	1
102	Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed By Autologous Stem Cell Transplant. Blood, 2014, 124, 5904-5904.	1.4	1
103	Specific Adoptive T-Cell Therapy for Viral and Fungal Infections. , 2018, , 395-411.		1
104	Future prospects for patient care utilizing autologous lymphoid and hematopoietic stem cells. Medicine and Health, Rhode Island, 2003, 86, 247-8.	0.1	1
105	Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for graft-versus-host disease in allogeneic antitumor cell therapy. Expert Opinion on Therapeutic Patents, 2007, 17, 459-464.	5.0	0
106	Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study. , 2015, 3, .		0
107	The Haploimmunostorm Syndrome: A Distinct Clinical Entity Seen in HLA-Haploidentical Cellular Immunotherapy.. Blood, 2006, 108, 2978-2978.	1.4	0
108	â€œLarge Pericardial Effusions as a Manifestation of Graft Versus Host Disease: a Single Institution Retrospective Studyâ€•. Blood, 2009, 114, 4659-4659.	1.4	0

#	Article	IF	Citations
109	Outcomes of Second Autologous Peripheral Blood Stem Cell Transplant in Multiple Myeloma Patients with Renal Dysfunction. Blood, 2014, 124, 5894-5894.	1.4	0
110	Outcomes in Patients on Hemodialysis Who Undergo High Dose Therapy Followed By Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma in the Era of Novel Agents. Blood, 2014, 124, 2518-2518.	1.4	0